70+
Study Sites
Headquartered at Fred Hutch in Seattle, the Network includes over 70 sites on four continents staffed by teams with expertise in vaccinology, immunology, and in conducting clinical trials.
100+
Clinical Trials
For more than 20 years, the HVTN has conducted all phases of clinical trials based on the latest developments in vaccinology and immunology for the prevention of HIV, tuberculosis and COVID-19.
74
Scholar Awards
We are investing in the next generation of HIV prevention researchers with grants and mentoring for African American/Black and Hispanic/Latinx medical students.
HVTN Mission
Our mission is to fully characterize the safety, immunogenicity, and efficacy of HIV vaccine candidates with the goal of developing a safe, effective vaccine as rapidly as possible for prevention of HIV globally.
Who We Are
We are the world’s largest publicly-funded international collaboration focused on the evaluation of vaccines to prevent HIV/AIDS.
What We Do
Our sites conduct all phases of clinical trials — from evaluating experimental vaccines for safety and immunogenicity to testing vaccine efficacy.
Get Involved
Worldwide, thousands of people have participated in HIV vaccine trials. Volunteers are the heroes of vaccine development.
It Takes a Village
The HIV Vaccine Trials Network is an international partnership of research scientists, clinical trial sites, laboratories, statisticians, regulators and ethicists, participants, volunteers and community representatives working with industry, academia, and governments in the global search for a preventive HIV vaccine.
Recent HVTN News & Announcements
"Intersections" video series launches in October
"Intersections", a new video series of one-on-one interviews exploring the intersections of science and daily life. Hosted by Dr. Stephaun Wallace, External Relations Director of both the CoVPN and HVTN, conversations will feature prominent figures in science, business, politics, the arts, sports, fashion, activism, news media, and technology.
Newly defined biomarker may accelerate clinical trials for vaccines to prevent HIV-1 infection
A study published in the August 22, 2022 issue of Nature Medicine identifies a new biomarker that appears effective as a surrogate endpoint to reliably predict the ability of broadly neutralizing monoclonal antibodies to prevent acquisition of HIV-1.
Read the Latest Community Compass Issue
In this edition we explore the intersection of faith and HIV with perspectives from HVTN Core staff and Faith Ambassadors, share information about the launch of a new marketing campaign aimed at supporting phase 1 enrollment, and share news of a new program aimed at increasing the scientific leadership of HVTN investigators.
